Enhancing the Effects of Alcohol Treatment With L-Carnitine
NCT ID: NCT05355311
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2024-09-27
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
NCT06446479
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
NCT03018236
Glutamatergic Modulation of Disordered Alcohol Use
NCT02539511
Human Laboratory Study of ASP8062 for Alcohol Use Disorder
NCT05096117
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L-Carnitine
L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 2.97 g daily for 6 weeks
L-carnitine
L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-carnitine
L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Self-report consuming alcohol ≥ 2 days/week on average in the past 28 days
3. Meets the DSM-5 criteria for alcohol use disorder (AUD)
4. Be interested in reducing alcohol use
5. Report at least mild depressive symptoms, as indicated by a score ≥ 14 on the Beck Depression Inventory II.
6. Be able to verbalize an understanding of the consent/assent form, able to provide written informed consent/assent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
7. Have parent permission, if younger than 18 years
8. Be able to take oral medication and be willing to adhere to the medication regimen
9. Complete all assessments required at screening and baseline.
10. Provide contact information of someone, such as a parent or other family member, who may be able to contact the subject in case of a missed appointment or follow-up assessment.
11. Agree to the schedule of visits, verbally acknowledge ability to attend each scheduled visit, participate in phone visits and report no scheduled events or a job that may substantially interfere with study participation.
12. Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months.
13. Agree (if the subject's sex is female and of childbearing potential) to use at least one reliable method of birth control, unless subject is surgically sterile, partner is surgically sterile, or subject is postmenopausal. Examples of reliable methods include (but may not be limited to):
1. oral contraceptives
2. contraceptive sponge
3. contraceptive skin patch
4. double barrier diaphragm (diaphragm/spermicidal or condom/spermicidal)
5. intrauterine contraceptive system
6. levonorgestrel implant
7. medroxyprogesterone acetate contraceptive injection
8. complete abstinence from sexual intercourse
9. hormonal vaginal contraceptive ring
Exclusion Criteria
2. Have significant alcohol withdrawal symptoms (score \> 10) on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-AR)
3. Have a coexisting moderate to severe substance use disorder other than cannabis and nicotine, as defined by DSM-5 criteria
4. Have a urine toxicology screen positive performed during screening or baseline for any of the following substances:
1. benzodiazepines
2. cocaine
3. opiates
4. amphetamines
5. buprenorphine
6. methadone
7. barbiturates
8. oxycodone
9. 3, 4-methylenedioxy-methamphetamine (MDMA, also known as ecstasy)
10. methamphetamines
5. Have been treated with a pharmacotherapy for alcohol use disorder or a carbonic anhydrase inhibitor within 30 days prior to randomization
6. Compelled to alcohol treatment by the juvenile justice system or has probation or parole requirements that might interfere with study participation
7. Have a history of liver disease or have clinically significant abnormal laboratory values, including elevation of liver enzymes (AST, ALT) 5-fold above the upper limit of normal (ULN), or bilirubin greater than 2 times the upper limit of normal.
8. History of renal impairment or renal stones, heart problems or defects, abnormal blood pressure, progressive neurodegenerative disorder, or clinically significant neurological disorders
9. Clinically significant physical abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis
10. Pregnancy, nursing, or refusal to use reliable birth control, if female of childbearing potential
11. Stable dose of any prescribed psychotropic medication (i.e., no dose changes in the 2 months prior to randomization)
12. Current or lifetime diagnosis of psychotic disorders or current bipolar disorder
13. Current suicidality risk
14. Known sensitivity to acetyl-l-carnitine
15. Be a subject who in the opinion of the investigator could not be safely withdrawn from alcohol without medical detoxification
16. Have a serious or unstable medical illness or any potentially life-threatening or progressive medical condition other than addiction that may compromise subject safety or study conduct
17. Have abnormal calculated creatinine clearance defined as \< 80 mL/min
18. Have data suggesting cirrhosis of the liver (albumin \< 3.2 g/dL, or ascites by physical exam)
18 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rhode Island Hospital
OTHER
Colorado State University
OTHER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Brown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Miranda, PhD
Role: PRINCIPAL_INVESTIGATOR
Brown University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brown University
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2101002877
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.